MedTrace Logo

The CATALYST Study

NCT05937698 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 6069

Last updated 2025-03-13

No results posted yet for this study

Summary

The CATALYST study is an implementation study that will characterize and assess the implementation of an enhanced service delivery package providing informed choice of pre-exposure prophylaxis (PrEP) products among women at PEPFAR sites in Kenya, Lesotho, South Africa, Uganda, and Zimbabwe.

Conditions

  • HIV Prevention

Sponsors & Collaborators

  • Wits Reproductive Health and HIV Institute

    collaborator OTHER

  • LVCT Health

    collaborator OTHER

  • Pangaea Zimbabwe Aids Trust

    collaborator OTHER

  • Jhpiego

    collaborator OTHER

  • United States Agency for International Development (USAID)

    collaborator FED

  • FHI 360

    lead OTHER

Principal Investigators

  • Virginia Fonner · FHI 360

  • Elizabeth Irungu · Jphiego

  • Kevin K'Orimba · LVCT Health

  • Nicolette Naidoo · Wits RHI

  • Carolyne Akello · FHI 360 Uganda

  • Emily Gwavava · Pangaea Zimbabwe Aids Trust

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-30
Primary Completion
2025-01-27
Completion
2025-01-27

Countries

  • Kenya
  • Lesotho
  • South Africa
  • Uganda
  • Zimbabwe

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05937698 on ClinicalTrials.gov